Healthcare Providers and Services
Company Overview of Northwestern Memorial Hospital
Northwestern Memorial Hospital operates as an academic medical center hospital in Chicago, Illinois. The company is also the teaching hospital for the Northwestern University Feinberg School of Medicine. It offers treatment in various specialties, including addiction psychiatry, adolescent psychiatry, allergy immunology, anesthesiology, autoimmune diseases, cardiology, clinical neurophysiology, colon and rectal surgery, critical care, cytopathology, dentistry, dermatology, emergency medicine, endocrinology, endodontics, family medicine, flow cytometry, GI endocrine surgery, gastroenterology, general surgery, geriatrics, gynecology, oncology, hematology, hepatology, and hospice and palliative...
251 East Huron Street
Chicago, IL 60611-2908
Founded in 1972
Key Executives for Northwestern Memorial Hospital
Executive Vice President and Chief Operating Officer
Chief executive officer of Northwestern Memorial Healthcare and President of Northwestern Memorial Healthcare
Senior Vice President of Human Resources
Vice President of General Services
Compensation as of Fiscal Year 2016.
Northwestern Memorial Hospital Key Developments
Northwestern Memorial Healthcare Names Julie Creamer as President of Northwestern Memorial Hospital
Oct 15 15
Northwestern Memorial HealthCare announced that it has named Julie Creamer as president of Northwestern Memorial Hospital (NMH), effective October 12. In this new role, Creamer will report to the office of the CEO. A member of NMHC's senior leadership team since 1996, Creamer most recently served as Senior Vice President of Administration for NMHC and Chief Transformation Executive for NMG. She has managed a diverse portfolio including quality, patient safety and information technology improvements and previously served as NMH's Chief Nurse Executive.
Northwestern Memorial Hospital Announces Results from New Phase II Clinical Study
Mar 6 15
Northwestern Memorial Hospital announced the results from a new phase II clinical study published in the journal Annals of Clinical and Translational Neurology. The study, 'Double-blind, Placebo-controlled Study of HGF Gene Therapy in Diabetic Neuropathy', reviewed the results of the study from the US and Korea involving 103 painful diabetic neuropathy (PDN) patients from 17 hospitals. According to the report, patients who received low dose (16 mg) of the gene therapy drug VM202-DPN, developed by ViroMed, experienced a significant pain reduction in 3 months and persisted up to 9 months. The most striking finding was that VM202 had much greater effects on patients not on conventional medicines. Patients who were not benefitting from current treatment options now have hope. 20% - 25% of diabetes patients suffer from the disease and feel intense pain with a slight graze or touch due to damaged nerve cells, but no treatments are available yet. Painkillers such as Lyrica and Cymbalta are used to only temporarily alleviate the pain, but these drugs are well known for the intolerable side effects. It is reported that because of the not-so-trivial side effects and/or the inconvenience associated with taking the drug daily, 60% - 70% of DPN patients do not or cannot take these drugs (Nature Reviews Drug Discovery, 2012 (11)). Results from this clinical study show that VM202-DPN, with only 2 treatments with 2 weeks interval, can induce high level of pain reduction for 3 - 9 months. As the results show signs of recovery of damaged neurons with almost no adverse effects associated with the drug, VM202-DPN is considered to become a very safe and effective drug. For these reasons, if the drug enters the market after phase III, it may transform the current PDN market. According to ViroMed, the published paper reports that VM202 had no drug related adverse effects and VM202 administered group had significantly better results compared to the placebo group. Pain reduction level and rate of patients who experience 50% or more pain reduction (50% responder rate) are some of the important measurements for efficacy. It is commonly acknowledged that when the pain level decreases by more than 1, it is considered clinically meaningful. In the Daily Pain Diary, which measures the changes in pain over 24 hour period, the differences in pain level between baseline and 3 months after injection were 1.5 for placebo group, 3.0 for VM202 16 mg group, and 1.9 for VM202 32 mg group. When compared to the placebo group, VM202 16 mg group showed increased pain level reduction of 1.5. Also, while only 17.6 % of patients in the placebo group showed 50% or more pain reduction, 48.4% of patients in the VM202 16 mg group showed 50% or more pain reduction. The difference in percentage between the two groups is 30.8%, which is higher difference than that of Lyrica1). Lyrica: Percentage of patients experiencing 50% or more pain reduction - Placebo: 14.5%, Lyrica 300 mg: 40%, difference of 25.5%. Neurology, 2004, Lesser H, et al.
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, the Northwestern Medicine Developmental Therapeutics Institute and Northwestern Memorial Hospital Launches New Research Program, Northwestern Onco-SET
Feb 5 15
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, in collaboration with the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) and Northwestern Memorial Hospital, has launched a new research program, Northwestern Onco-SET (Sequence, Evaluate, Treat), to provide a more personalized, precision medicine option for cancer patients by combining oncology with genomics. This program will initially focus on patients with any type of cancer that is not responsive to traditional therapies. Onco-SET personalizes cancer care for each patient by sequencing the individual genetic profile of their tumors – known as genomic profiling – and evaluating the results to provide the treatments or clinical trials that will benefit them most. Some of these approaches include site-agnostic, pathway-driven treatments, which use therapies developed to target the specific genetic abnormalities of one type of cancer and applies them to treating a different kind of cancer if it shares the same genetic abnormalities. To evaluate and discuss the best treatment options for each patient, Onco-SET created the Lurie Cancer Center's Molecular Tumor Board, which brings together a group of experts to review every tumor's genomic profile. The board is comprised of a wide spectrum of cancer specialists, including pathologists, medical, surgical and radiation oncologists, as well as cancer geneticists, genome biologists, molecular scientists, bio-ethicists and bioinformaticists. Treatment options made available to the Molecular Tumor Board through Onco-SET include novel therapies from a variety of early-stage clinical trials. By offering cancer patients care within Onco-SET, the program is also expanding the Lurie Cancer Center's pre-clinical research by collecting and analyzing detailed data from each patient's tumor genomic profiles. The information collected will allow Northwestern Medicine researchers to identify new treatment patterns and important genomic pathways to help develop novel approaches to cancer treatment.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|